Goto et al., ascertained IL17RB as a cancer stem cell (CSC)-specific cell surface marker in human CRC and confirmed that continuous ablation of IL17RB-expressing CSCs robustly subdued tumor growth in vivo [40]. The gene discussed is IL17RB; the disease is neoplasm.